Redefining Neurodegeneration: From Plaques and Pathology to Systemic Network Dysfunction

Q: Question – What is the most compelling evidence that neurodegeneration is a whole-body network problem?

Answer – Several converging lines stand out: - The gut-brain axis in Parkinson’s. - Constipation, REM sleep behaviour disorder and loss of smell can precede Parkinson’s motor symptoms by a decade or more. Aggregates of alpha-synuclein are found in the enteric nervous system and may travel via the vagus nerve to the brainstem. Epidemiologically, people who have had a truncal vagotomy appear to have lower Parkinson’s risk, consistent with a gut–to–brain propagation route. - Systemic inflammation and dementia. - Elevated inflammatory markers (CRP, IL‑6, TNF‑α) in midlife predict higher risk of cognitive decline decades later. Microglia – the brain’s immune cells – switch into a chronically activated state in Alzheimer’s, Parkinson’s and ALS. Peripheral infections, chronic periodontal disease and even severe COVID-19 appear to accelerate cognitive deterioration in vulnerable individuals. - Metabolic and vascular signatures. - Type 2 diabetes, insulin resistance and midlife hypertension are among the most robust, modifiable risk factors for Alzheimer’s. The concept of “type 3 diabetes” – brain insulin resistance – is controversial but captures a real observation: impaired energy metabolism and vascular health correlate tightly with both pathology and symptoms. - Genetics that point beyond neurons. - Major Alzheimer’s risk alleles such as APOE4, TREM2 and complement pathway genes are expressed in glia and immune cells, not just neurons. Many PD and ALS genes relate to lysosomal function, mitochondrial quality control and protein clearance – fundamental cellular processes across tissues. Together, this suggests that in a subset of patients, neurodegenerative disease is the terminal expression of years of network-level dysfunction involving immunity, metabolism, vasculature and the microbiome, with the brain registering the final, most visible symptom: loss of function.

sharonshieldsconsu

Sep 7

5 min read

For decades, neurodegenerative drug development has run on a similarly simple story.

Alzheimer’s is amyloid. Parkinson’s is dopamine. ALS is motor neurons dying.

We built programs, platforms and pipelines around those narratives. We went after plaques and tangles, misfolded proteins and missing transmitters. We poured billions into clearing amyloid from the brain, replacing dopamine in the striatum, protecting neurons from oxidative stress.

That story isn’t exactly wrong. But it is looking increasingly incomplete.

Question – What if neurodegeneration isn’t primarily a brain disorder, but a network disorder?

Answer – In the last fifteen years, a different picture has been emerging. Alzheimer’s, Parkinson’s and other neurodegenerative diseases look less like isolated brain failures and more like the downstream expression of system-wide network disturbances.

Chronic inflammation, metabolic dysfunction, immune ageing, vascular health and the microbiome all appear to feed into whether and how quickly neurons get sick. Misfolded proteins like amyloid-β, tau and alpha-synuclein may be critical nodes in this network, but they are not the whole map.

In Parkinson’s, misfolded alpha-synuclein can first appear in the gut and olfactory system, years before tremor. In Alzheimer’s, midlife obesity, diabetes, hypertension and sleep apnoea all measurably shift dementia risk. Central nervous system pathology is increasingly hard to separate from peripheral immune activation, vascular damage and disrupted cellular housekeeping (autophagy, proteostasis, mitochondrial function).

Neurodegeneration may be less “the brain went wrong” and more “the network failed, and the brain was one of the casualties.”

Question – What is the most compelling evidence that neurodegeneration is a whole-body network problem?

Answer – Several converging lines stand out:

The gut-brain axis in Parkinson’s.
Constipation, REM sleep behaviour disorder and loss of smell can precede Parkinson’s motor symptoms by a decade or more. Aggregates of alpha-synuclein are found in the enteric nervous system and may travel via the vagus nerve to the brainstem. Epidemiologically, people who have had a truncal vagotomy appear to have lower Parkinson’s risk, consistent with a gut–to–brain propagation route.
Systemic inflammation and dementia.
Elevated inflammatory markers (CRP, IL‑6, TNF‑α) in midlife predict higher risk of cognitive decline decades later. Microglia – the brain’s immune cells – switch into a chronically activated state in Alzheimer’s, Parkinson’s and ALS. Peripheral infections, chronic periodontal disease and even severe COVID-19 appear to accelerate cognitive deterioration in vulnerable individuals.
Metabolic and vascular signatures.
Type 2 diabetes, insulin resistance and midlife hypertension are among the most robust, modifiable risk factors for Alzheimer’s. The concept of “type 3 diabetes” – brain insulin resistance – is controversial but captures a real observation: impaired energy metabolism and vascular health correlate tightly with both pathology and symptoms.
Genetics that point beyond neurons.
Major Alzheimer’s risk alleles such as APOE4, TREM2 and complement pathway genes are expressed in glia and immune cells, not just neurons. Many PD and ALS genes relate to lysosomal function, mitochondrial quality control and protein clearance – fundamental cellular processes across tissues.

Together, this suggests that in a subset of patients, neurodegenerative disease is the terminal expression of years of network-level dysfunction involving immunity, metabolism, vasculature and the microbiome, with the brain registering the final, most visible symptom: loss of function.

Question – Could a network view change how we match patients to treatments?

Answer – This is where the near-term opportunity may be greatest.

If neurodegeneration is a family of network disorders rather than a single brain disease, then “Alzheimer’s” or “Parkinson’s” as diagnostic labels are too blunt for precision therapeutics. We may need to sub-stratify patients by:

Inflammatory profile (high vs low systemic and CNS inflammation)
Metabolic state (insulin resistant vs insulin sensitive; mitochondrial markers)
Vascular risk and burden (microinfarcts, white matter disease, endothelial biomarkers)
Microbiome and gut-derived signatures
Genetic and polygenic risk architectures

In that world:

Some patients might benefit most from aggressive amyloid/tau or alpha-synuclein targeting, because misfolded protein burden is their dominant driver.
Others might respond better to immune and metabolic modulation, because inflammation or energy failure are doing the real damage.
Yet others might require combined regimens: a CNS biologic plus a GLP‑1 analog, or a neuroprotective small molecule plus targeted cardiovascular and microbiome interventions.

Clinical trials would need to be designed differently, with smarter enrichment, longitudinal biomarker panels and combinations that acknowledge brain, immune, metabolic and gut axes as one integrated system rather than separate domains.

Precision neurology has been an aspiration; network-aware stratification and biomarker-guided combinations may be what finally makes it operational.

The larger shift

Reframing neurodegeneration as a network disorder doesn’t minimise the devastation of losing neurons, memories or movement. It contextualises those losses inside a broader, multi-system failure that often starts decades earlier and extends beyond the skull.

That reframe has consequences:

For drug development – from single targets to network-informed portfolios and combinations.
For clinical trials – from monolithic “Alzheimer’s populations” to biologically stratified cohorts.
For prevention and care – from late-stage symptom control to earlier, multi-system risk modification.

The “plaque and tangle” story shaped thirty years of neurodegeneration R&D.

The network story is only beginning.

Need discreet talent intelligence or leadership research support in life sciences? Get in touch to book a discussion, click here

References

Neurodegeneration research: Advances in clinical translational research and therapeutic approaches. PMC (2018). This review is useful for background on translational progress and key disease mechanisms, including immune and inflammatory pathways in Alzheimer’s disease.https://pmc.ncbi.nlm.nih.gov/articles/PMC6111039/
Neurodegeneration enters the era of functional genomics. Science (2024). Useful for the shift toward cell-type-specific and mechanism-informed discovery using functional genomics in neurons, microglia and astrocytes.https://www.science.org/doi/10.1126/science.adk5693
Neurodegeneration: 2024 update. PMC (2024). A broad recent review covering microglia/T-cell interactions, viral exposures, cerebrovascular pathology and polygenic risk in neurodegeneration.https://pmc.ncbi.nlm.nih.gov/articles/PMC11736941/
Advancing Treatments and Cures for Neurodegenerative Diseases. NIH report (2025). Helpful for framing the current therapeutic landscape, biomarker progress and ongoing amyloid-targeting trials.https://www.nih.gov/sites/default/files/2025-02/20240729-forward-advancing-treatments-cures-neurodegenerative-diseases.pdf
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging. Nature Medicine (2025). Strong source for the biomarker-driven, data-sharing and precision-medicine direction of the field.https://www.nature.com/articles/s41591-025-03834-0
Large-scale proteomics project seeks cures for neurodegenerative disease. Nature Medicine commentary / PMC version (2025). A useful companion piece describing the GNPC and its relevance for biomarker and drug discovery.https://pmc.ncbi.nlm.nih.gov/articles/PMC12950189/
Global collaboration: A new frontier in neurodegeneration research. Science (2025). Good for the scale of the GNPC and the move toward collaborative proteomic discovery.https://www.science.org/content/article/global-collaboration-new-frontier-neurodegeneration-research
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances. Nature Reviews / PMC-linked article (2025). Useful for the theme that aging biology, metabolism and cellular maintenance pathways are central to neurodegeneration.https://www.nature.com/articles/s41392-025-02145-7
Neurodegenerative diseases need more mechanism-informed trials. Nature Medicine (2026). Very useful for the argument that the field needs better biological stratification and trial design.https://www.nature.com/articles/s41591-026-04258-0
Recent advances in preventing neurodegenerative diseases. PMC (2021). A broad review that can support discussion of emerging preventive and neuroprotective approaches.https://pmc.ncbi.nlm.nih.gov/articles/PMC8725650/
Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer’s, Parkinson’s, and ALS. PubMed record (2024). Helpful as a general review of molecular mechanisms, biomarkers, gene editing and microbiome-related therapeutic ideas.https://pubmed.ncbi.nlm.nih.gov/39684324/?fc=None&ff=20241218060130&v=2.18.0.post9+e462414
Editorial: New challenges and future perspectives in neurodegeneration. PMC (2022). Useful for general framing about where the field is heading.https://pmc.ncbi.nlm.nih.gov/articles/PMC9590607/